ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SHP Shire

4,690.00
0.00 (0.00%)
17 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Shire LSE:SHP London Ordinary Share JE00B2QKY057 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4,690.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Shire to Participate at the Deutsche Bank 42nd Annual Health Care Conference

25/04/2017 12:00pm

PR Newswire (US)


Shire (LSE:SHP)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Shire Charts.

LEXINGTON, Massachusetts, April 25, 2017 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Jeff Poulton, Chief Financial Officer, will participate at the Deutsche Bank 42nd annual health care conference, at the InterContinental Boston Hotel on Thursday, May 4, 2017 at 10:40 AM EDT (15:40 BST).

A live audio webcast will be available on the Presentations and Webcasts section of Shire's Investor website at http://investors.shire.com/presentations-and-webcasts/. Subsequently, a replay of the webcast will be available on this same website for approximately 90 days.

NOTES TO EDITORS 

About Shire 

Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

http://www.shire.com

For further information please contact: 

Investor Relations
Ian Karp
ikarp@shire.com
+1-781-482-9018

Robert Coates
rcoates@shire.com
+44-1256-894874

Copyright 2017 PR Newswire

1 Year Shire Chart

1 Year Shire Chart

1 Month Shire Chart

1 Month Shire Chart

Your Recent History

Delayed Upgrade Clock